.Pharmacolibrary.Drugs.ATC.A.A02BC08 .Pharmacolibrary.Drugs.ATC.A.A02BC08| name: | Vonoprazan | |
| ATC code: | A02BC08 | route: | oral |
| compartments: | 1 | |
| dosage: | 20 | mg |
| volume of distribution: | 168 | L |
| clearance: | 18.8 | L/h |
| other parameters in model implementation | ||
Vonoprazan is a potassium-competitive acid blocker (P-CAB) used for the treatment of acid-related diseases such as gastroesophageal reflux disease (GERD) and peptic ulcer. It is approved and used in various countries for gastric acid suppression.
Pharmacokinetic parameters reported for healthy adult volunteers after single oral administration.
Echizen, H (2016). The First-in-Class Potassium-Competitive Acid Blocker, Vonoprazan Fumarate: Pharmacokinetic and Pharmacodynamic Considerations. Clinical pharmacokinetics 55(4) 409–418. DOI:10.1007/s40262-015-0326-7 PUBMED:https://pubmed.ncbi.nlm.nih.gov/26369775
Jenkins, H, et al., & Warrington, S (2015). Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects. Alimentary pharmacology & therapeutics 41(7) 636–648. DOI:10.1111/apt.13121 PUBMED:https://pubmed.ncbi.nlm.nih.gov/25707624